drugset
drugset / Trial / NCT05246514

A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC

NCT05246514 ↗

Phase 2 Active not recruiting 72 enrolled AstraZeneca Daiichi Sankyo · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of T-DXd in participants with HER2 mutant metastatic non-squamous NSCLC.

Timeline

Start
2022-07-13
Primary completion
2024-11-04
Completion
2026-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Trastuzumab deruxtecan Monoclonal antibody — Intravenous

Indications

No indication recorded.